S. Tsrtsarevska1, N. Geshkovski1, M. G. Dodov1, S. Chalish2, S. Dimchevska1, K. Gorachinova11Farmatsevtski fakultet,Univerzitet Sv. Kiril i Metodij, Skopje,Makedonija 2Farmatsevtski fakultet, Univerzitet Khadzhetepe, 06100 Ankara,TurtsijaVOVEDNasochuvanjeto na antikantser lekovite kon tumornite promeni voorganizmot so pomosh na nanopartikulirani sistemi (NP) mozhe dase postigne so t.n. pasiven i aktiven targeting. Vo osnovata napasivniot targeting e iskoristuvanjeto na anatomskite ipatofizioloshkite abnormalnosti na tumornata vaskulatura shtoovozmozhuva akumulatsija na lekot na mestoto na patoloshkitepromeni kako rezultat na podobrena permeablinost i zadrshka t.e.t.n. EPR (Enhanced Permeability and Retention) efekt. EPR efektotpretstavuva 'zlaten standard' pri dizajniranje na novi antikantseragensi. Vakviot pristap mozhe da ja zgolemi bioraspolozhlivostai efikasnosta na lekot [1]. Pri razvoj i optimizatsija na NP,posebno vnimanie treba da se obrne na odredeni nivni fizichko-khemiski karakteristiki, kako shto se goleminata i distributsijatapo golemina, kapatsitetot za enkapsulatsija, kako i mozhnostite zanivna funktsionalizatsija. Za podgotovka na NP bea upotrebeni Poly(D,L-lactide-co-glycolide)acid (PLGA) i tri-blok kopolimer Pluronic F127 (F127).Ulogata na F127 e da obezbedi khidrofilni karakteristiki nakhidrofobnata NP povrshina. Kako model lek e upotrebenirinotekan khidrokhlorid (IR-HCl), khidrosolubilna lekovitasupstantsija. MATERIJALI I METODIPLGA (laktat/glikolat = 85/15) e nabavena od Sigma, Germanija,dodeka F127 e doniran od BASF, Germanija. IR-HCl e nabaven od Bio-tech Co., Kina. Site drugi upotrebeni khemiski supstantsii se soanalitichki stepen na chistota.PODGOTOVKA I KARAKTERIZATsIJA NA NPNP se dobieni so primena na modifitsirana naopretsipitatsiskapostapka [2,3]. Pod identichni uslovi bea podgotveni triformulatsii so razlichna kolichina na polimeri i identichnakolichina na lek. Sostavot na podgotvenite formulatsii e prikazhanvo Tabela 1. Tabela 1. Sostav na NP so inkorporiran IR-HClNP bea karatkterizirani vo odnos na nivnata morfologija (Jeol-SEM 6400, Japonija), golemina na chestichki, indeks napolidisperznost (PDI) i zeta potentsijal (Zetasizer Nano Series,Nano-ZS, Malvern Instruments Ltd., UK). Efikasnosta naenkapsulatsija (EE) na lekot vo NP beshe opredelena so primena navalidiran HPLC metod, po razdeluvanje so gel filtratsionakhromatografija (Sephadax G-25 column) i/ili tsentrifugalnaultrafiltratsija (Vivaspin 20, 1000 KDa, Sartorius Stedim,Germanija). Brzinata na osloboduvanje na lekot e sledena pod sinkuslovi vo PBS, vo tek na 5 dena. So primena na standarden metod nadepletsija [4] beshe opredelena kolichinata na F127 inkorporiranavo NP, kako i posledovatelno adsorbiranata kolichina na F127 napovrshinata na NP.Rezultati i diskusijaNP dobieni so modifitsirana nanopretsipitatsija, robusen ireprodutsibilen proizvoden protses, imaa prifatliva sferichnamorfologija i mazna povrshina. Goleminata na chestichkite,indeksot na polidisperznost i EE se prikazhani vo Tabela 2.Goleminata na NP koj e vo rang od 20-200 nm, obezbeduva mpzhnostza edinstvena interaktsija so bioloshkite sistemi na molekularnonivo, shto e vo prilog na posakuvaniot EPR efekt. So ogled dekaformulatsiite bea podgotveni pri identichni uslovi, mozhe da sezakluchi deka najverojatno initsijalnata kolichina na F127 imavlijanie na goleminata na NP, odnosno, povisoka kontsentratsijarezultira so pomali NP. Niskite vrednosti na zeta-potentsijalot(-1 do -5 mV) se vo prilog na posakuvanaiot nizok stepen naopsonizatsija, so shto se namaluva mozhnosta da bidat prepoznaeniod RES, pri toa prodolzhuvajkji go vremeto na prestoj vosistemskata tsirkulatsija.Tabela 2. Golemina, PDI, EE na NP (sredna +- SD, n = 6)Kolichinata na initsijalno osloboden lek zavisi od sostavot na NP,t.e. se zgolemuva so zgolemuvanje na kolichinata na F127 (Sl.1).Kinetikata na osloboduvanje najdobro se objasnuva so Korsmeyer-Peppas modelot, koj ukazhuva deka difuzijata e glavniot kontrolenmekhanizam. So ogled deka opsonizatsijata i eliminatsijata na NPpreku RES e glavna prechka za EPR efektot, potrebno e povrshinatana NP da bide sterichki stabilizirana. Ova mozhe da se postigne soinkorporiranje i adsorptsija na F127 na povrshinata na NP.Kolichinite na inkorporiran i adsorbiran F127, opredeleni sometod na depletsija, se prikazhani vo Tabela 3. Povisokainitsijalna kolichina na F127 obezbeduva pogolema khidrofilnnostna povrshinata na NP.Slika 1. Profil na in vitro osloboduvanje na IR-HCl ood podgotvenitenanochestichki vo PBS pH 7.4 na 37+-0.5 0C (sredna+- SD, n = 3)308Makedonski farmatsevtski bilten 57 (dodatok), 2011FARMATsEVTSKA TEKhNOLOGIJA I BIOFARMATsIJAposter prezentatsiiPETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOTabela 3. Kolichina na inkorporiran i adsorbiran F127 napovrshinata na NP (mg F127/mg PLGA +- SD)ZAKLUChOKIspituvanjta pokazhaa deka podgotvenite NP imaat (i) soodvetnagolemina i povrshinski napon (ii) efikasna EE (iii) kontroliranoosloboduvanje i (iv) sterichki stabilizirana khidrofilnapovrshina. Podgotvenite NP se vetuvachki sistemi za targetiranjena tsvrsti tumori so pomosh na EPR efekt, no neopkhodna eponatamoshna optimizatsija za da se iskoristi nivniot tselosenpotentsijal. Ponatamoshnata rabota kje bide fokusirana nasoodvetnosta i primenata na ovie nosachi in vivo na zhivotinskimodeli. LITERATURA1. Maeda, H. (2001). The enhanced permeability and retention (EPR) effect in tumorvasculature: the key role of tumor-selective macromolecular drug targeting, AdvEnzyme Regul 41: 189-207.2. Glavas, M., Calis, S., Simonoska M., Geskovski, N., Goracinova, K. (2011). Colloidalcarriers for anticancer drug delivery - formulation aspects, Proceedings ofInternational Symposium on Drug Research and Development, Antalya, Turkey 3. Simonoska Crcarevska, M., Geskovski, N., Kuzmanovska, S., Glavas Dodov, M.,Calis, S., Goracinova, K. (2011). Preparation and biological evaluation of irinotecanloaded biodegradable nanocarriers for tumour delivery by EPR effect, Proceedingsof 3rd PharmSciFair, Prague, Czech Republic4. Shar, J. A., Obey, T. M., Cosgrove, T. (1998). Adsorption studies of polyethers Part1. Adsorption onto hydrophobic surfaces.Colloid Surface A 136 (1-2): 21-33.PHARMACY-BASED SURVEY OF PATIENTEXPERIENCES AND TREATMENT EFFEC-TIVENESS OF ACUTE DIARRHEA USINGPROBIOTICS IN R. OF MACEDONIAT. Sterjeva1, K. Goracinova2, M. Glavas Dodov21Euro-Farm Dooel, Bitola, Macedonia2Institute of Pharmaceutical Technology, Faculty of Pharmacy, Ss Cyriland Methodius University, MacedoniaINTRODUCTIONDiarrhea is an increase in the frequency of bowel movements or adecrease in the form of stool and can be classified into acute andchronic. Acute diarrhea is a common problem that usually lasts 1 or 2days and goes away on its own. The principal components of thetreatment of acute diarrhea are fluid and electrolyte replacement,dietary modifications and drug therapy. Giving probiotics inconjunction with rehydration fluids reduced the duration of diarrheaby around a day and reduced the risk of diarrhea lasting four or moredays by 59% (1).Probiotics are "live microorganisms which when administered inadequate amounts confera health benefit on the host" (WHO and FAOdefinition) (2). Many commercially available products with probiotics,which are regulated as dietary supplements and foods,consist of yeastor bacteria. These products may contain a single microorganism or amixture of several species. They are available as capsules, tablets,packets or powders and are also contained in various fermentedfoods,most commonly yogurt or dairy drinks (3). Some of the claims for whichresearch supports a beneficial effect of probiotic consumptioninclude: improving intestinal tract health, enhancing the immunesystem, synthesizing and enhancing the bioavailability of nutrients,reducing symptoms of lactose intolerance, decreasing the prevalenceof allergy in susceptible individuals, and reducing risk of certaincancers. Mechanisms of action for probiotics include production ofantimicrobial substances, modification of toxins, interference withattachment, stimulation of the immune system, lowering intestinalpH or a combination of above mentioned mechanisms (4). In the previous years many probiotic products as dietary supplementshave been established on the pharmaceutical market in Macedoniaand they are now widely used by consumers and in clinical practice. In recent years, there has been an increasing drive to promote self-care in patients and the pharmacy profession has an opportunity to as-sume a key role in progressing this agenda. Therefore, the aim of thisstudy was to investigate the patient experiences of purchasing probi-otics for treatment of acute diarrhea in Macedonian community phar-macies and to explore the safety and usage pattern by collecting datafrom patients and their pharmacist.METHODSThe survey was a pharmacy-based observational study in 50 commu-nity pharmacies in different regions in R. Macedonia. This descriptivestudy was performed on 191 patients and 92 pharmacists, interviewedon voluntary and confidential basis.RESULTS AND DISCUSSION In the course of the conducted study, 52% of the patients stated thatthey take medicines as recommended by their doctor, while 27% ofthe patients reported that they follow the pharmacist recomme n da -ti on. Newspapers and the internet were not viewed as primary sourcesof advice on probiotics use in acute diarrhea treatment. Also, 88.8% ofpatients were familiar with the therapeutical indications, the dosingand the manner the medicine used. Symptoms characteristic for acute diarrhea were pointed out by 60%of the patients, most of which stated that they feel these symptomsfor less than two days prior to consulting a professional for assistance.Identical results have been acquired both from the surveyedpharmacist, which received the informations from their patients. The largest percentage of the patients, 38.8%, could not locate thereason causing this symptom, 20.4% stated the common cold as amajor symptom, while 15.6% of the patients reported consuming foodand drinks of suspicions quality, as a symptom. Consistency in theanswers provided by the patients and the pharmacist was present inthese answers, as well. For treatment of acute diarrhea, 51.6% of the patients tended to pur-chase over the counter medicines, while 20.4% took medicineobtained only with a prescription by a doctor. The pharmacistsindicated that 51.1 % of the patients do not use another medicine fortreatment of diarrhea prior to their coming in the pharmacy.38% of the surveyed pharmacist recommend medicines that containprobiotic culture as their choice for treatment of seasonal diarrheas,and 57% of the pharmacist reported that the key factor forrecommending the product is its efficacy.As a major reason for recommendation of medicine, higest percentageof pharmacists (27.7%) stated that they make the choice on basis of309Macedonian Pharmaceutical Bulletin 57 (suppl), 2011PHARMACEUTICAL TECHNOLOGY AND BIOPHARMACYposter presentationsFIFTH CONGRESS OF PHARMACY OF MACEDONIA WITH INTERNATIONAL PARTICIPATIONtheir previous positive experience with the medicine they have foundout in communication with their patients and with the physician. For37.2 % of the patients, the crucial factor for choosing of medicine isthe recommendation they get from the medical professionals. Thelargest number of examined patients, 42%, consider that themedicines bought over the counter are safer and have less adverseeffects compared to the medicines bought with a doctor'sprescription. Having completed the therapy, lasting not more than 5 days with themajority of patients, nearly 80% of respondents reported that thetherapy was successful, and 86% of them had no adverse effects. REFERENCES1.http://www.sciencecodex.com/probiotics_shorten_diarrhea_episodes 2. G. Reid, J. Jass, M. T. Sebulsky, J. K. McCormick. 2003. Potential Uses ofProbiotics in Clinical Practice. Clinical Microbiology Reviews, 16/4, 658-672.3. N.T. Williams. 2010. Probiotics. American Journal of Health-System Pharmacy,67/6, 449-458.4. E. Murali, B.T.V.V. Kavitha, J. Srikanth, G. Velmani. 2010. Probiotics as PotentialTherapies in Human Gastrointestinal Health. International Journal ofPharmaceutical Sciences, 1, 96-110.ISKUSTVA NA PATsIENTITE IPROTsENKA NA EFIKASNOSTA NATRETMANOT NA AKUTNA DIJAREA PRIUPOTREBA NA PROBIOTITsI - OPISNASTUDIJA NIZ JAVNITE APTEKI VO R.MAKEDONIJASterjeva T.1, Gorachinova K.2, Glavash Dodov M.21Euro-farm. Dooel, Bitola, Makedonija2Institut za farmatsevtska tekhnologija, Farmatsevtski fakultet,Univerzitet "Sv.Kiril i Metodij", Skopje, MakedonijaVOVEDDijareata se definira kako zgolemena frekventsija na dvizhenjena fekalnite materii vo debeloto tsrevo shto rezultira soporemeteno formiranje na stolitsata. Dijareata mozhe da bideakutna ili khronichna.